<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283816</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB-00012501</org_study_id>
    <secondary_id>GCRC#1083</secondary_id>
    <nct_id>NCT00283816</nct_id>
  </id_info>
  <brief_title>Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy</brief_title>
  <official_title>Metabolic Impact of Oral Contraceptives With or Without Metformin in Obese Adolescents With Polycystic Ovary Syndrome (PCOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may
      increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic
      state. This study is to determine whether metformin added to oral contraceptive therapy in
      adolescent women with PCOS improves metabolic state.The study will also test a lifestyle
      improvement program to reduce weight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic Ovary Syndrome (PCOS) is a heterogeneous condition characterized by chronic
      anovulation and androgen excess that occurs in 4-8% of unselected adult women. Although signs
      and symptoms of the disorder typically appear at the time of puberty, diagnosis is often
      delayed until adulthood. At least 50% of adult women with PCOS are obese, resulting in a more
      severe clinical picture. Obesity among adolescents has been increasing in recent years, with
      overrepresentation of females who show evidence of hyperandrogenism and irregular periods,
      suggesting an association of obesity and PCOS at an early age. Recent data, however, have
      drawn attention to the long-term risks of PCOS, including diabetes and cardiovascular
      disease. Insulin resistance plays a critical role in the pathophysiology of PCOS and is
      thought to be the metabolic abnormality most closely linked to an increased risk of diabetes
      and heart disease. Traditional treatments with oral contraceptives are associated with
      reduction in serum androgens and improvements in menstrual cycles in adolescents with PCOS,
      however these have not been well-studied in obese adolescents. Oral contraceptives may worsen
      the dyslipidemia seen in obese women with PCOS and do not address the insulin resistance.
      Metformin, an insulin sensitizing agent, has been shown to improve metabolic features of
      PCOS, but combination therapy with oral contraceptives has never been studied in the obese
      adolescent with PCOS.

      The major hypothesis of this proposal is that metformin will improve the metabolic profile of
      obese adolescent girls with PCOS treated with oral contraceptives. Additionally, a secondary
      hypothesis will be that compliance with a concurrent lifestyle modification program with be
      associated with the most significant improvements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Abdominal Fat as Measured by Waist Circumference.</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in waist circumference measured in cms used as a measure of abdominal adiposity, pre minus post intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Weight Post Minus Pre Intervention.</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Body mass index change in adolescents enrolled in lifestyle intervention program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone Change</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in total testosterone post minus pre intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sex Hormone Binding Globulin (SHBG)</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>SHBG concentration post minus pre-intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg. tabs 2 tabs BID for duration of study</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Metformin Hydrochloride Tablets, 500 mg.</other_name>
    <other_name>manufacturer: Mylan Pharmaceuticals, Morgantown, WV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive Pill</intervention_name>
    <description>Yasmin, drospirenone and ethinyl estradiol 28 tablets
1 tab daily for duration of study</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
    <other_name>Yasmin 28 tablets</other_name>
    <other_name>Manufacturer: Berlex, Montville, NJ 07045</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Management Program</intervention_name>
    <description>Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise &amp; behavior modification skills on a regular weekly basis over the 24 week study</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaire</intervention_name>
    <description>Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test</intervention_name>
    <description>Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.
Performed twice during study, at baseline and conclusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood work</intervention_name>
    <description>Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal Ultra Sound</intervention_name>
    <description>transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.
Performed twice during study, at baseline and conclusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual-energy x-ray absorptiometry (DEXA scan)</intervention_name>
    <description>Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules, two capsules BID</description>
    <arm_group_label>0</arm_group_label>
    <other_name>placebo formulation: 240 mg. lactose powder USP</other_name>
    <other_name>in size 3 capsules from Capsugel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Age 12-18 years; Menstrual irregularity; Overweight; Must be able to
        swallow capsules; At lease 6 months since onset of first menstrual cycle.

        Exclusion Criteria:Diabetes; Kidney or Liver disease; Tobacco use; Depression or Bipolar
        Disease; Contraindication to exercise; Weight &gt; 300 lbs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Hoeger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2006</study_first_submitted>
  <study_first_submitted_qc>January 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2006</study_first_posted>
  <results_first_submitted>April 8, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2011</results_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Kathleen M. Hoeger, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Overweight Adolescent Girls</keyword>
  <keyword>Irregular Menstrual Cycles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects given a placebo in addition to oral contraceptive and lifestyle program</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects given a placebo in addition to oral contraceptive and lifestyle program</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="1.6"/>
                    <measurement group_id="B2" value="15.8" spread="1.6"/>
                    <measurement group_id="B3" value="15.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Abdominal Fat as Measured by Waist Circumference.</title>
        <description>Change in waist circumference measured in cms used as a measure of abdominal adiposity, pre minus post intervention</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>2000mg of metformin in addition to oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill in addition to oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Abdominal Fat as Measured by Waist Circumference.</title>
          <description>Change in waist circumference measured in cms used as a measure of abdominal adiposity, pre minus post intervention</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="8.6"/>
                    <measurement group_id="O2" value="-1.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight Post Minus Pre Intervention.</title>
        <description>Body mass index change in adolescents enrolled in lifestyle intervention program</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin 2000mg in addition to oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill in addition to oral contraceptive</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight Post Minus Pre Intervention.</title>
          <description>Body mass index change in adolescents enrolled in lifestyle intervention program</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.7"/>
                    <measurement group_id="O2" value="-1.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone Change</title>
        <description>Change in total testosterone post minus pre intervention</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>2000mg of metformin in addition to oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill in addition to oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone Change</title>
          <description>Change in total testosterone post minus pre intervention</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.7" spread="21.7"/>
                    <measurement group_id="O2" value="-27.6" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sex Hormone Binding Globulin (SHBG)</title>
        <description>SHBG concentration post minus pre-intervention</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>2000mg of metformin in addition to oral contraceptive</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill in addition to oral contraceptive pill</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sex Hormone Binding Globulin (SHBG)</title>
          <description>SHBG concentration post minus pre-intervention</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.4" spread="31.9"/>
                    <measurement group_id="O2" value="-58" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects given a placebo in addition to oral contraceptive and lifestyle program</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen M. Hoeger, MD, MPH</name_or_title>
      <organization>University of Rochester Medical Center</organization>
      <phone>585-275-7891</phone>
      <email>Kathy_Hoeger@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

